共查询到20条相似文献,搜索用时 11 毫秒
1.
2.
3.
Jay Kataria Daniel Rivera Andrea Grin David Edward Reed David Mario Rodrigues 《Neurogastroenterology and motility》2024,36(1):e14706
Biopsies have important value in assessing for nonerosive reflux disease. 相似文献
4.
6.
7.
8.
9.
10.
Mocco J Ransom ER Komotar RJ Sergot PB Ostapkovich N Schmidt JM Kreiter KT Mayer SA Connolly ES 《Journal of neurology》2006,253(10):1278-1284
Background While efforts have been made to document short-term outcomes following poor grade aneurysmal subarachnoid hemorrhage (aSAH),
no data exist concerning the degree of delayed improvement in neurological function. Here we assess cognitive function, level
of independence, and quality of life (QoL) over 12 months following poor grade aSAH.
Methods Data on definitively treated poor grade patients (Hunt and Hess grade IV or V) surviving 12 months post-aSAH were obtained
through a prospectively maintained SAH database. Demographic information, medical history, and clinical course were analyzed.
Health outcomes assessments completed by surviving patients at discharge (DC), three months (3 M) and 12 months (12 M) follow-up,
including the Telephone Interview for Cognitive Status (TICS), Barthel Index (BI), and Sickness Impact Profile (SIP), were
used to evaluate cognitive function, level of independence, and QoL.
Findings Fifty-six poor grade patients underwent aneurysm-securing intervention and survived at least 12 months post-aSAH. Thirty-five
(63%) surviving patients underwent health outcomes assessments at DC, 3 M and 12 M post-aSAH. A majority of patients had improved
scores on the TICS (DC to 3 M: 91%; 3 M to 12 M: 82%), BI (DC to 3 M: 96%; 3 M to 12 M: 92%), and SIP (3 M to 12 M: 80%) following
aSAH. Using paired-sample analyses, significant improvement on each test was observed.
Conclusion A substantial portion of patients experience cognitive recovery, increased independence, and improved QoL following poor grade
aSAH. Delayed follow-up assessments are necessary when evaluating functional recovery in this population. These findings have
the potential to impact poor grade aSAH management and prognosis.
Received in revised form: 24 July 2005 相似文献
11.
12.
13.
14.
Badih J. Daou Sravanthi Koduri B. Gregory Thompson Neeraj Chaudhary Aditya S. Pandey 《CNS Neuroscience & Therapeutics》2019,25(10):1096-1112
Aneurysmal subarachnoid hemorrhage (aSAH) continues to be associated with significant morbidity and mortality despite advances in care and aneurysm treatment strategies. Cerebral vasospasm continues to be a major source of clinical worsening in patients. We intended to review the clinical and experimental aspects of aSAH and identify strategies that are being evaluated for the treatment of vasospasm. A literature review on aSAH and cerebral vasospasm was performed. Available treatments for aSAH continue to expand as research continues to identify new therapeutic targets. Oral nimodipine is the primary medication used in practice given its neuroprotective properties. Transluminal balloon angioplasty is widely utilized in patients with symptomatic vasospasm and ischemia. Prophylactic “triple‐H” therapy, clazosentan, and intraarterial papaverine have fallen out of practice. Trials have not shown strong evidence supporting magnesium or statins. Other calcium channel blockers, milrinone, tirilazad, fasudil, cilostazol, albumin, eicosapentaenoic acid, erythropoietin, corticosteroids, minocycline, deferoxamine, intrathecal thrombolytics, need to be further investigated. Many of the current experimental drugs may have significant roles in the treatment algorithm, and further clinical trials are needed. There is growing evidence supporting that early brain injury in aSAH may lead to significant morbidity and mortality, and this needs to be explored further. 相似文献
15.
16.
17.
18.
19.